Columbia University Irving Medical Center, New York, NY, USA.
Oncologist. 2024 Aug 5;29(8):653-657. doi: 10.1093/oncolo/oyae103.
The rapid advancement of sequencing technologies has led to the identification of numerous mutations in cancer genomes, many of which are variants of unknown significance (VUS). Computational models are increasingly being used to predict the functional impact of these mutations, in both coding and noncoding regions. Integration of these models with emerging genomic datasets will refine our understanding of mutation effects and guide clinical decision making. Future advancements in modeling protein interactions and transcriptional regulation will further enhance our ability to interpret VUS. Periodic incorporation of these developments into VUS reclassification practice has the potential to significantly improve personalized cancer care.
测序技术的快速发展导致在癌症基因组中鉴定出许多突变,其中许多是意义不明的变体(VUS)。计算模型越来越多地被用于预测这些突变在编码和非编码区域中的功能影响。将这些模型与新兴的基因组数据集集成,将深化我们对突变影响的理解,并指导临床决策。在建模蛋白质相互作用和转录调控方面的未来进展将进一步增强我们解释 VUS 的能力。定期将这些进展纳入 VUS 重新分类实践中,有可能显著改善癌症的个体化治疗。